Why is Ipsen stock sliding today?

Ipsen stock is experiencing a decline of 3.8%, currently trading at €157.6, following a significant downgrade from Barclays. This analyst downgrade reignites concerns regarding the company's medium-term earnings trajectory. Barclays has reduced its rating from Equalweight to Underweight and lowered its price target from EUR170 to EUR155.

The core concerns center around three factors: the accelerating sales erosion of Somatuline due to increased generic competition, the potential for a rival's CAM2029 drug candidate to surpass Somatuline by late 2026 or early 2027, and the substantial reinvestment burden ahead of later-stage pipeline launches. These challenges are seen as creating meaningful downside risk to 2027-2029 earnings estimates.

This situation echoes an earlier downgrade by Jefferies, which highlighted CAM2029 competition that could erode Somatuline's long-term revenue by over 35%. Ipsen's H1 2026 earnings call acknowledged that generic competition for Somatuline would pressure sales in the second half of 2026 and into 2027, as well as the impact of a new entrant in second-line oncology on Onivyde revenues.

While the broader market conditions did not offer much relief, with U.S. indices trading lower, the recovery of Ipsen's stock from its 52-week range of €109.9–€174.0 appears vulnerable due to the deteriorating analyst consensus. The Barclays downgrade served as the immediate trigger, but it compounded pre-existing competitive and structural concerns that the market had been monitoring since the H1 results, ultimately pushing Ipsen to its session low of €156.6 during today's trading.